BBNX — Beta Bionics, Inc.

Summary of Beta Bionics Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Net Sales: $27.6 million, a 57% increase year-over-year.
• Gross Margin: 59.5%, up 864 basis points from Q1 2025, driven by a growing pharmacy channel and lower material costs.
• Operating Expenses: $40.7 million, a 47% increase compared to $27.6 million in Q1 2025, attributed to sales force expansion and R&D investments.
• Cash Position: Approximately $240 million in cash and investments, deemed sufficient to fund key initiatives.

2. Strategic Updates and Business Highlights:

• Continued growth in new patient starts, with a high percentage (high 30s) accessing the iLet through the pharmacy channel.
• Expansion of the sales force, with plans to add at least 20 new territories in 2026 to drive adoption.
• Progress on product development, including the Mint patch pump and bihormonal system, with confidence in achieving FDA clearance for Mint by the end of 2027.
• Launch of the Bionic Insights feature for healthcare providers, aimed at enhancing patient management and treatment recommendations.

3. Forward Guidance and Outlook:

• Revenue Guidance: Revised to $131 million to $136 million for 2026, up from previous guidance of $130 million to $135 million.
• Pharmacy Mix: Expected to be 37% to 39% of new patient starts reimbursed through the pharmacy channel.
• Gross Margin Outlook: Raised to 57.5% to 59.5% for the full year, reflecting strong Q1 performance and expectations of continued growth.
• Anticipation of increased operating expenses due to ongoing sales force expansion and marketing investments.

4. Challenges and Points of Concern:

• New Patient Starts: Experienced a decline of more than 10% but less than 20% compared to Q4 2025, consistent with seasonal patterns.
• FDA Warning Letter: The company is addressing concerns raised in a January warning letter regarding its quality management system, with ongoing remediation efforts.
• Competitive Pressures: While the company sees no immediate threats from competitors, increased competition in the pharmacy channel could dilute market share over time.

5. Notable Q&A Insights:

• Pharmacy Channel Dynamics: Management noted that increased competition in the pharmacy channel could benefit all players by normalizing the market and reducing pricing pressure.
• Sales Force Expansion: The expansion is both filling new territories and enhancing coverage in existing areas, with expectations for meaningful contributions from newly onboarded territories.
• Type 2 Diabetes Indication: The company acknowledges the potential growth from type 2 diabetes patients but emphasizes the need for FDA approval to market the product specifically for this indication.
• Customer Acquisition Costs: Current sales and marketing expenses are high relative to revenue, but management believes that building a strong installed base will reduce these costs over time.

Overall, Beta Bionics demonstrated strong financial growth in Q1 2026, with positive strategic developments and an optimistic outlook for the year, despite facing some challenges and competitive pressures.